Study shows remdesivir as primary COVID treatment is a total bust
Sixteen months into this virus, our government has nothing to offer us in terms of treatment in the hospital but remdesivir at $3,100 a dose and zero treatment options at the critical early stage, when serious complications can be pre-empted. Now, a new study from the University of Iowa shows what we knew all along – that remdesivir failed to reduce mortality one iota. Why are we to believe the same government entities about embracing the clot shots and shunning so many other cheaper and effective treatments after spending billions and losing countless lives on a failed drug?
After 62 studies, 32 of them randomized controlled trials, establishing ivermectin as an effective treatment and an even more effective preventative to keep people out of the hospital in the first place, our government refuses to endorse its use and Big Tech continues to censor it. They claim they need more studies. Yet not a single randomized controlled trial showed remdesivir to be effective before they dove in headfirst and the NIH made it the only approved antiviral treatment for COVID. Now, a University of Iowa study published in JAMA Network Open on Thursday has shown that remdesivir was a complete bust.
Among the 2,334 US veterans studied in 124 hospitals, a higher share of remdesivir patients (12.2 percent) who took part in the study died than patients in the control group (10.6 percent). Moreover, on average, remdesivir patients spent six days in the hospital, while control group patients spent only three.
Previously, last October, the World Health Organization found that use of remdesivir in 11,000 patients across 400 hospitals in the world failed to lower the mortality rate or truncate time of stay in the hospital.
Take a look at this chart of treatment protocols for COVID hospital patients from the NIH, and you will see that aside from remdesivir, the only other treatment they offer is dexamethasone as the corticosteroid of choice to treat inflammation.
Again, dexamethasone was approved after just one randomized controlled trial last year, when ivermectin had over two dozen. This new study from the University of Iowa seems to show that dexamethasone is also a bust because outcomes did not improve among those who received that steroid along with remdesivir, as opposed to the control group that did not. In other words, after 16 months of research by doctors on numerous helpful antiviral and anti-inflammatory drugs, as well as more effective corticosteroids, the government has ensured that we have not advanced one iota in treating this virus. This is truly criminal and probably the gravest scandal of COVID.
Contrast this to ivermectin, which is available for $25. A Cochrane-standard (the highest level review) meta-analysis of ivermectin against COVID-19 by Bryant-Lawrie, which has been published in the American Journal of Therapeutics, concluded that ivermectin reduced fatality in hospitalized patients by 62%. But more important is getting people to use this immediately in an outpatient setting and, for vulnerable people, even preventively. The study found that "ivermectin prophylaxis reduced covid-19 infection by an average 86%."
Fair use excerpt. Read the whole article here.